Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-7.36 Insider Own0.90% Shs Outstand45.07M Perf Week7.10%
Market Cap6.29B Forward P/E- EPS next Y-7.09 Insider Trans-40.67% Shs Float45.07M Perf Month6.61%
Income-288.00M PEG- EPS next Q-1.71 Inst Own- Short Float9.67% Perf Quarter45.18%
Sales26.70M P/S235.39 EPS this Y-46.90% Inst Trans0.01% Short Ratio5.33 Perf Half Y69.24%
Book/sh29.24 P/B4.77 EPS next Y-4.30% ROA-25.20% Target Price127.47 Perf Year164.36%
Cash/sh24.30 P/C5.74 EPS next 5Y- ROE-32.20% 52W Range37.05 - 145.40 Perf YTD126.01%
Dividend- P/FCF- EPS past 5Y47.20% ROI-27.00% 52W High-4.09% Beta2.03
Dividend %- Quick Ratio14.40 Sales past 5Y47.50% Gross Margin- 52W Low276.38% ATR6.17
Employees378 Current Ratio14.40 Sales Q/Q943.70% Oper. Margin- RSI (14)61.71 Volatility4.37% 4.99%
OptionableYes Debt/Eq0.13 EPS Q/Q-8.50% Profit Margin- Rel Volume0.63 Prev Close139.10
ShortableYes LT Debt/Eq0.13 EarningsNov 01 AMC Payout- Avg Volume816.87K Price139.45
Recom2.30 SMA206.04% SMA5016.41% SMA20045.31% Volume511,552 Change0.25%
Oct-16-17Upgrade Evercore ISI In-line → Outperform
Oct-11-17Resumed Jefferies Hold $126
Oct-09-17Reiterated Maxim Group Buy $100 → $170
Oct-06-17Resumed Goldman Buy $186
Oct-02-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-05-17Reiterated Wells Fargo Outperform $134 → $158
Aug-17-17Initiated Evercore ISI In-line $102
Aug-07-17Reiterated Morgan Stanley Equal-Weight $103 → $105
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jun-16-17Downgrade Standpoint Research Buy → Reduce
Jun-02-17Upgrade Maxim Group Hold → Buy $100
May-30-17Initiated Standpoint Research Buy $110
Feb-27-17Downgrade Maxim Group Buy → Hold
Feb-06-17Downgrade ROTH Capital Buy → Neutral
Dec-01-16Reiterated Maxim Group Buy $57 → $87
Oct-14-16Reiterated Leerink Partners Outperform $67 → $80
Oct-14-16Downgrade Cantor Fitzgerald Hold → Sell $42 → $37
Oct-14-16Downgrade Cantor Fitzgerald Hold → Sell
Sep-22-16Resumed ROTH Capital Buy $87
Aug-04-16Reiterated Maxim Group Buy $105 → $85
Oct-12-17 08:10AM  Today's Research Reports on Stocks to Watch: MannKind Corporation and Bluebird Bio ACCESSWIRE
Oct-06-17 04:16PM  bluebird bio to Present at Chardan Gene Therapy Conference Business Wire
Oct-04-17 03:00PM  bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine Business Wire
Oct-03-17 10:42AM  Why bluebird bio, Inc. Stock Gained 10% in September Motley Fool
Oct-02-17 04:10PM  Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily -8.66%
03:56PM  Bluebird Bio: So Much for That Gilead Boost Barrons.com
12:00PM  Here's Why Bluebird Bio (BLUE) Stock Is Falling Today Zacks
07:40AM  Featured Company News - Bluebird Bio Declares Treatment of 1st Patient with 2nd Anti-BCMA CAR T bb21217 in CRB-402 Phase-1 Study ACCESSWIRE
Sep-29-17 10:54AM  Why Biotech and Tech Will Push Stocks Higher In 4Q Investopedia
08:37AM  Should You Be Concerned About bluebird bio Incs (BLUE) Risks? Simply Wall St.
Sep-28-17 04:57PM  Bluebird Hits High On Bullish Report Highlighting Blood Drugs Investor's Business Daily +9.76%
04:30PM  Why BlackBerry, AbbVie, and bluebird bio Jumped Today Motley Fool
04:05PM  bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma Business Wire
02:38PM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio Motley Fool
Sep-26-17 09:32AM  3 Biotech Stocks With Major Catalysts in October Motley Fool
Sep-22-17 07:03AM  Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy? InvestorPlace
Sep-20-17 08:00AM  bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors Business Wire
Sep-19-17 07:09AM  Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade InvestorPlace
Sep-15-17 08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical ACCESSWIRE
Sep-13-17 08:00AM  bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 Business Wire
Sep-06-17 03:16PM  Here's What Lifted bluebird bio Inc. Stock 40% Higher in August Motley Fool
08:00AM  bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting Business Wire
Sep-01-17 08:00AM  bluebird bio to Present at Investor Conferences in September Business Wire
Aug-31-17 05:32PM  ETFs with exposure to bluebird bio, Inc. : August 31, 2017 Capital Cube +10.98%
03:42PM  Why bluebird bio Inc Continued Its March Higher Again Today Motley Fool
Aug-30-17 06:46PM  Cramer pinpoints the trend that could lead to a surge in ... CNBC Videos +9.86%
06:33PM  Cramer: This trend could lead to surge in takeovers CNBC Videos
04:37PM  Why bluebird bio Inc Jumped Higher Today Motley Fool
01:59PM  Novartis: A New $475,000 Drug Barrons.com
12:38PM  Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost? Barrons.com
08:49AM  Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal Zacks
Aug-29-17 03:52PM  Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition Zacks
08:44AM  bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : August 29, 2017 Capital Cube
08:20AM  Today's Research Reports on Trending Tickers: bluebird bio Inc. and Juno Therapeutics Inc. ACCESSWIRE
Aug-28-17 05:39PM  ETF Topper: Booming Biotech Barrons.com +8.64%
01:40PM  Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today Motley Fool
12:49PM  Gilead: What the Heck is CAR-T, How Much is Too Much, and Other Kite Acquisition Questions Barrons.com
11:41AM  Biotech stocks surge on Gilead's Kite Pharma acquisition MarketWatch
Aug-24-17 11:39AM  bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-09-17 08:18AM  Is This Why bluebird bio Dipped 10.5% in July? Motley Fool
08:00AM  bluebird bio to Present at Wedbush PacGrow Healthcare Conference Business Wire
Aug-07-17 05:18PM  bluebird bio, Inc. Value Analysis (NASDAQ:BLUE) : August 7, 2017 Capital Cube
03:20PM  bluebird bio Pauses During 2017 Data Blitz Motley Fool
Aug-04-17 02:34AM  Bluebird reports 2Q loss Associated Press
Aug-02-17 04:05PM  bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress Business Wire
Jul-25-17 05:30PM  Biotech still has more room to run: Technician CNBC Videos
08:19AM  bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : July 25, 2017 Capital Cube
Jul-24-17 02:25PM  ETFs with exposure to bluebird bio, Inc. : July 24, 2017 Capital Cube
Jul-14-17 07:43PM  For Now, GE Remains a Dog of the Dow; Dimon Makes J.P. Proud - ICYMI Friday TheStreet.com
01:07PM  ETFs with exposure to bluebird bio, Inc. : July 14, 2017 Capital Cube
Jul-13-17 09:48AM  Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others TheStreet.com
Jul-12-17 05:08PM  Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug Investor's Business Daily
Jul-11-17 09:20AM  bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : July 11, 2017 Capital Cube
Jul-09-17 07:28AM  Billions of Dollars on the Line for Celgene With These 3 Small Biotechs Motley Fool
Jul-05-17 10:31PM  How a Conference Caused Bluebird Bio's Shares to Rocket 33% in June Motley Fool
Jun-30-17 04:16PM  Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit? Investor's Business Daily
01:10PM  The Cure For Cancer? Look At Your Blood Investor's Business Daily
10:40AM  Bluebird Bio: Too Much Good News? Barrons.com
Jun-28-17 05:54PM  Blue Apron IPO Prices At 10, Low End Of Lowered Range Investor's Business Daily
Jun-27-17 06:29PM  bluebird bio Announces Pricing of Public Offering of Common Stock Business Wire
11:17AM  Time to Take Profits in Bluebird Bio TheStreet.com
Jun-26-17 04:06PM  bluebird bio Announces Proposed Public Offering of Common Stock Business Wire
04:04PM  bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy (CALD) Business Wire
Jun-23-17 05:01PM  Why BlackBerry, Sysco, and bluebird bio Slumped Today Motley Fool -5.49%
07:00AM  bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent -Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting Business Wire
07:00AM  bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting Business Wire
Jun-20-17 12:57PM  These Biotechs Are Leading The Sector To A 3-Month High Today Investor's Business Daily
Jun-16-17 07:41AM  3 Top-Performing Biotech Stocks This Week Motley Fool
Jun-14-17 08:17AM  The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch InvestorPlace
Jun-13-17 09:29AM  Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool
Jun-11-17 01:33PM  What Investors Missed in the Market Last Week Motley Fool
Jun-08-17 04:46PM  Bluebird Bio Appoints Two New Directors to its Board TheStreet.com
04:05PM  bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors Business Wire
02:07PM  bluebird bio, Inc. Value Analysis (NASDAQ:BLUE) : June 8, 2017 Capital Cube
07:46AM  J.P. Morgan analyst crowns Bluebird Bio the clear winner at major cancer conference MarketWatch
Jun-07-17 04:53PM  Why bluebird bio Inc. Flew Higher Again Today Motley Fool +11.15%
04:32PM  Why Hawaiian Holdings, MBIA, and bluebird bio Jumped Today Motley Fool
08:22AM  3 Promising Stocks to Buy Now Motley Fool
07:00AM  Blood and bone marrow therapies grab spotlight at world's top cancer meeting Reuters
Jun-06-17 04:58PM  This Small Biotech Soared On Its Celgene-Partnered Trial Investor's Business Daily +7.56%
03:58PM  bluebird bio Inc (BLUE) Leads the Way in the Next Wave of CAR-Ts SmarterAnalyst
01:40PM  Why bluebird bio Inc Flew Higher Today Motley Fool
08:55AM  Bluebird Bio Is Liked by Analysts, Cognizant Isn't TheStreet.com
08:35AM  bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session Zacks
08:04AM  bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : June 6, 2017 Capital Cube
Jun-05-17 05:28PM  Bluebird Bio shares pop on what CEO calls very exciting cancer news CNBC +8.50%
09:46AM  UPDATE: Bluebird Bio stock rises 7.4% on positive data from ongoing early-stage clinical trial MarketWatch
09:34AM  Bluebird Bio stock rises 5% on positive data from ongoing early-stage clinical trial MarketWatch
07:30AM  Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free TheStreet.com
07:30AM  bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
Jun-02-17 12:49PM  Stocks to watch during ASCO CNBC Videos +6.25%
08:15AM  Bluebird Bio stock jumps 7% after Maxim Group upgrades to buy MarketWatch
Jun-01-17 08:00AM  bluebird bio to Present at Two Investor Conferences in June Business Wire +5.11%
May-23-17 08:06AM  bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 23, 2017 Capital Cube
08:00AM  bluebird bio Announces Collaboration with Duke Universitys Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy Business Wire
May-22-17 01:24PM  ETFs with exposure to bluebird bio, Inc. : May 22, 2017 Capital Cube
May-18-17 06:09AM  bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting Business Wire
May-17-17 05:10PM  Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting TheStreet.com
05:00PM  bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
May-12-17 08:55AM  bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 12, 2017 Capital Cube
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leschly NickPresident and CEOOct 17Sale145.0510,8231,569,840262,409Oct 19 04:13 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise5.504,90026,95232,205Oct 11 04:37 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale129.944,900636,72427,305Oct 11 04:37 PM
Gregory Philip DChief Scientific OfficerOct 02Option Exercise50.511,25063,13830,734Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.504,00022,00219,977Oct 04 04:02 PM
Gregory Philip DChief Scientific OfficerOct 02Sale131.822,250296,60228,484Oct 04 04:02 PM
Davidson DavidChief Medical OfficerOct 02Sale131.314,000525,24915,977Oct 04 04:02 PM
MARAGANORE JOHNDirectorSep 14Option Exercise2.0918,86839,43424,711Sep 18 04:09 PM
MARAGANORE JOHNDirectorSep 14Sale131.2118,8682,475,7335,843Sep 18 04:09 PM
Vachon MarkDirectorSep 12Option Exercise30.476,000182,8208,000Sep 14 04:09 PM
Vachon MarkDirectorSep 12Sale126.826,000760,9232,000Sep 14 04:09 PM
Walsh Jeffrey T.Chief FinancialSep 11Option Exercise5.504,90026,95232,205Sep 13 04:07 PM
Walsh Jeffrey T.Chief FinancialSep 11Sale125.734,900616,06527,305Sep 13 04:07 PM
Gregory Philip DChief Scientific OfficerSep 01Option Exercise50.511,25063,13831,734Sep 06 04:06 PM
Leschly NickPresident and CEOSep 01Option Exercise5.506,36435,005295,732Sep 05 04:01 PM
Davidson DavidChief Medical OfficerSep 01Option Exercise5.5012,00066,00527,977Sep 06 04:06 PM
Gregory Philip DChief Scientific OfficerSep 01Sale126.062,250283,63529,484Sep 06 04:06 PM
Davidson DavidChief Medical OfficerSep 01Sale129.0812,0001,548,90415,977Sep 06 04:06 PM
Leschly NickPresident and CEOSep 01Sale130.0422,5002,925,983273,232Sep 05 04:01 PM
Walsh Jeffrey T.Chief FinancialAug 31Option Exercise5.5012,00066,00539,305Sep 05 04:02 PM
Schenkein David PDirectorAug 31Option Exercise8.162,00016,3125,176Sep 05 04:02 PM
LYNCH DANIELDirectorAug 31Option Exercise5.505002,7503,300Sep 05 04:01 PM
Schenkein David PDirectorAug 31Sale115.072,000230,1453,176Sep 05 04:02 PM
Walsh Jeffrey T.Chief FinancialAug 31Sale125.0112,0001,500,09127,305Sep 05 04:02 PM
Leschly NickPresident and CEOAug 31Sale115.0924,3332,800,461289,368Sep 05 04:01 PM
LYNCH DANIELDirectorAug 31Sale120.0050060,0002,800Sep 05 04:01 PM
Leschly NickPresident and CEOAug 30Sale115.1825,6672,956,307313,701Aug 31 04:16 PM
Walsh Jeffrey T.Chief FinancialAug 28Option Exercise5.501,2506,87628,555Aug 30 04:17 PM
Walsh Jeffrey T.Chief FinancialAug 28Sale107.061,250133,82627,305Aug 30 04:17 PM
MARAGANORE JOHNDirectorAug 24Option Exercise2.0913,83928,92419,682Aug 28 04:17 PM
MARAGANORE JOHNDirectorAug 24Sale95.8111,0851,062,1088,597Aug 28 04:17 PM
Mandell JamesDirectorAug 14Sale95.951,00095,9501,000Aug 15 04:05 PM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,2506,87628,555Aug 14 04:03 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale95.411,250119,26527,305Aug 14 04:03 PM
Gregory Philip DChief Scientific OfficerAug 07Option Exercise50.5150025,25531,234Aug 09 04:01 PM
Gregory Philip DChief Scientific OfficerAug 07Sale99.0075074,25030,484Aug 09 04:01 PM
Sullivan EricPrincipal Accounting OfficerAug 04Option Exercise53.6844523,8906,119Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 04Sale95.2144542,3705,674Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Option Exercise22.204169,2376,090Aug 07 04:02 PM
Sullivan EricPrincipal Accounting OfficerAug 03Sale92.3541638,4185,674Aug 07 04:02 PM
MARAGANORE JOHNDirectorAug 02Sale96.742,754266,4255,843Aug 28 04:17 PM
Gregory Philip DChief Scientific OfficerAug 01Option Exercise50.5175037,88332,234Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Option Exercise2.093,0006,27018,977Aug 03 04:04 PM
Gregory Philip DChief Scientific OfficerAug 01Sale93.081,500139,62030,734Aug 03 04:04 PM
Davidson DavidChief Medical OfficerAug 01Sale92.373,000277,09915,977Aug 03 04:04 PM
Walsh Jeffrey T.Chief FinancialJul 10Option Exercise5.502,50013,75129,805Jul 12 04:15 PM
Walsh Jeffrey T.Chief FinancialJul 10Sale99.892,500249,72427,305Jul 12 04:15 PM
Davidson DavidChief Medical OfficerJul 07Sale100.491,200120,58315,977Jul 11 04:07 PM
Gregory Philip DChief Scientific OfficerJul 06Option Exercise50.511,25063,13833,734Jul 10 04:03 PM
Cole JasonChief Legal OfficerJul 06Option Exercise22.535,126115,48920,927Jul 07 04:04 PM
Gregory Philip DChief Scientific OfficerJul 06Sale103.832,250233,61631,484Jul 10 04:03 PM
Sullivan EricPrincipal Accounting OfficerJul 05Option Exercise51.753,580185,2529,987Jul 07 04:03 PM
Davidson DavidChief Medical OfficerJul 05Option Exercise2.095,00010,45022,177Jul 07 04:03 PM
Sullivan EricPrincipal Accounting OfficerJul 05Sale107.284,313462,7065,674Jul 07 04:03 PM
Davidson DavidChief Medical OfficerJul 05Sale105.285,000526,39517,177Jul 07 04:03 PM
Sullivan EricPrincipal Accounting OfficerJun 29Option Exercise36.626,728246,41113,194Jun 30 04:01 PM
Sullivan EricPrincipal Accounting OfficerJun 29Sale108.966,787739,5306,407Jun 30 04:01 PM
Leschly NickPresident and CEOJun 27Sale108.0525,0002,701,164349,368Jun 29 04:01 PM
LYNCH DANIELDirectorJun 23Option Exercise3.794,00015,1466,800Jun 27 04:05 PM
LYNCH DANIELDirectorJun 23Sale109.094,000436,3622,800Jun 27 04:05 PM
LYNCH DANIELDirectorJun 20Option Exercise2.092,5005,2165,300Jun 22 04:04 PM
LYNCH DANIELDirectorJun 20Sale120.032,500300,0702,800Jun 22 04:04 PM
Gregory Philip DChief Scientific OfficerJun 16Sale109.283,295360,08532,484Jun 22 04:03 PM
Walsh Jeffrey T.Chief FinancialJun 12Option Exercise2.092,5005,21629,805Jun 14 04:18 PM
Walsh Jeffrey T.Chief FinancialJun 12Sale109.532,500273,83127,305Jun 14 04:18 PM
LYNCH DANIELDirectorJun 08Option Exercise2.092,5005,2165,300Jun 12 04:57 PM
LYNCH DANIELDirectorJun 08Sale110.202,500275,4882,800Jun 12 04:57 PM
Cole JasonChief Legal OfficerJun 07Option Exercise50.5143521,97216,236Jun 08 04:19 PM
Cole JasonChief Legal OfficerJun 07Sale100.0543543,52215,801Jun 08 04:19 PM
Cole JasonChief Legal OfficerJun 06Option Exercise25.4316,810427,41532,611Jun 08 04:19 PM
Walsh Jeffrey T.Chief FinancialJun 06Option Exercise2.092,5005,21629,805Jun 08 04:21 PM
LYNCH DANIELDirectorJun 06Option Exercise2.092,2634,7223,663Jun 08 04:20 PM
Gregory Philip DChief Scientific OfficerJun 06Option Exercise50.511,00050,51037,279Jun 08 04:20 PM
LYNCH DANIELDirectorJun 06Sale100.142,263226,6221,400Jun 08 04:20 PM
Walsh Jeffrey T.Chief FinancialJun 06Sale100.052,500250,13527,305Jun 08 04:21 PM
Gregory Philip DChief Scientific OfficerJun 06Sale99.041,500148,56035,779Jun 08 04:20 PM
Cole JasonChief Legal OfficerJun 06Sale100.2216,8101,684,70515,801Jun 08 04:19 PM
Davidson DavidChief Medical OfficerJun 05Option Exercise2.091,0002,09018,177Jun 07 04:46 PM
LYNCH DANIELDirectorJun 05Option Exercise2.091,0002,0862,400Jun 07 04:47 PM
LYNCH DANIELDirectorJun 05Sale90.001,00090,0021,400Jun 07 04:47 PM
Davidson DavidChief Medical OfficerJun 05Sale90.001,00090,00217,177Jun 07 04:46 PM
Davidson DavidChief Medical OfficerJun 01Option Exercise2.092,0004,18019,177Jun 05 04:33 PM
Gregory Philip DChief Scientific OfficerJun 01Option Exercise50.5175037,88337,779Jun 05 04:34 PM
Gregory Philip DChief Scientific OfficerJun 01Sale75.621,500113,43036,279Jun 05 04:34 PM
Davidson DavidChief Medical OfficerJun 01Sale75.422,000150,84917,177Jun 05 04:33 PM
LYNCH DANIELDirectorMay 25Option Exercise2.092,0004,1733,400May 30 04:07 PM
LYNCH DANIELDirectorMay 25Sale80.002,000160,0011,400May 30 04:07 PM
Walsh Jeffrey T.Chief FinancialMay 10Option Exercise5.501,2506,87628,555May 12 04:20 PM
Walsh Jeffrey T.Chief FinancialMay 10Sale88.771,250110,96627,305May 12 04:20 PM
Davidson DavidChief Medical OfficerMay 01Option Exercise2.093,0006,27020,177May 03 04:24 PM
Gregory Philip DChief Scientific OfficerMay 01Option Exercise50.5175037,88338,529May 03 04:26 PM
Gregory Philip DChief Scientific OfficerMay 01Sale88.071,500132,10937,029May 03 04:26 PM
Davidson DavidChief Medical OfficerMay 01Sale88.743,000266,20817,177May 03 04:24 PM
LYNCH DANIELDirectorApr 27Option Exercise2.091,0002,0862,400May 01 04:05 PM
LYNCH DANIELDirectorApr 27Sale90.011,00090,0101,400May 01 04:05 PM
Cole JasonChief Legal OfficerApr 26Option Exercise22.533,75084,48815,801Apr 28 04:04 PM
LYNCH DANIELDirectorApr 25Option Exercise2.092,0004,1733,400Apr 27 04:08 PM
LYNCH DANIELDirectorApr 25Sale86.752,000173,5001,400Apr 27 04:08 PM
Walsh Jeffrey T.Chief FinancialApr 10Option Exercise5.501,2506,87628,555Apr 12 04:12 PM
Walsh Jeffrey T.Chief FinancialApr 10Sale87.381,250109,22527,305Apr 12 04:12 PM